Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly

Area of Science:

• Hematology
• Oncology
• Virology

Background:

• Epstein-Barr virus positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a rare B-cell lymphoproliferative disorder (B-LPD) affecting individuals over 50.
• Patients typically present with moderate to severe clinical B-symptoms, indicating an aggressive disease course.

Purpose of the Study:

• To characterize the clinical, morphological, and immunophenotypic features of EBV+ DLBCL in the elderly.
• To differentiate EBV+ DLBCL from other B-cell lymphoproliferative disorders and classical Hodgkin lymphoma.

Main Methods:

• Histopathological examination of affected tissues, revealing effacement of normal architecture by atypical lymphoid cells and giant cells.
• Immunophenotypic analysis of neoplastic cells, including expression of CD20, CD79a, PAX-5, CD30, LMP-1, EBNA-2, and EBER positivity.
• Assessment of proliferation marker Ki-67 and exclusion of markers like CD15, CD10, and BCL6.

Main Results:

• EBV+ DLBCL of the elderly exhibits variable cellular composition and mitotic activity, historically classified into low-grade polymorphic and high-grade monomorphic types, now recognized as high-grade lymphomas.
• Neoplastic cells express B-cell markers (CD20, CD79a, PAX-5) and EBV-encoded proteins (LMP-1, EBNA-2, EBER), with variable CD30 expression and generally negative CD15, CD10, and BCL6.
• The disease is characterized by high Ki-67 expression, indicating rapid proliferation.

Conclusions:

• EBV+ DLBCL of the elderly is a distinct, aggressive high-grade lymphoma with a median survival of approximately 2 years.
• These patients demonstrate reduced responsiveness to standard chemotherapy regimens compared to other B-LPDs.
• Accurate diagnosis through comprehensive pathological and molecular analysis is crucial for appropriate management and differentiating it from other lymphoid malignancies.